Department of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.
School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2086774. doi: 10.1080/21645515.2022.2086774. Epub 2022 Jun 8.
Mumps cases were reported frequently when a routine dose measles-mumps-rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine (MuCV) was assessed using surveillance data in this study. Mumps cases and immunization information were retrieved from the National Notifiable Disease Reporting System (NNDRS) and the Zhejiang Provincial Immunization Information System (ZJIIS), respectively. Mumps cases of children born from 2006 to 2010 were included. Vaccine effectiveness by dose was calculated using the screening method. A total of 956 mumps cases were identified, of whom 754 (78.9%) had received one dose of MuCV; 108 (11.3%) had received two doses; 94 (9.8%) were unvaccinated. The coverage of one-dose MuCV in the 2006-2010 birth cohorts ranged from 91.6% to 98.9%. Except the 2009 birth cohort in which the coverage of two doses of MuCV was 55.1%, the others were less than 10%. Vaccine effectiveness (VE) of one dose ranged from 47.4% to 86.0%, while VE of two doses ranged from 64.0% to 92.4%. The VE of one and two doses of MuCV waned over time, but the VE of two doses was consistently higher than that of one dose in the same period. The vaccine schedule with two-dose MMR should be implemented among children in Quzhou. The optimal age for the second dose needs to be further evaluated.
在衢州，常规剂量麻疹-腮腺炎-风疹（MMR）疫苗高覆盖率时，常报告流行性腮腺炎病例。为控制流行性腮腺炎暴发，开展了麻疹-腮腺炎（MM）补充免疫活动（SIA）。本研究利用监测数据评估了一剂和两剂含腮腺炎成分疫苗（MuCV）的效果。腮腺炎病例和免疫信息分别从国家法定传染病报告系统（NNDRS）和浙江省免疫信息系统（ZJIIS）中检索。纳入 2006 年至 2010 年出生的儿童腮腺炎病例。使用筛选法计算剂量疫苗效力。共确定了 956 例腮腺炎病例，其中 754 例（78.9%）接种了一剂 MuCV；108 例（11.3%）接种了两剂；94 例（9.8%）未接种。2006-2010 年出生队列中一剂 MuCV 的覆盖率在 91.6%至 98.9%之间。除了 2009 年出生队列中两剂 MuCV 的覆盖率为 55.1%外，其他队列均低于 10%。一剂疫苗的效力（VE）在 47.4%至 86.0%之间，两剂疫苗的 VE 在 64.0%至 92.4%之间。MuCV 的一剂和两剂疫苗效力随时间推移而减弱，但在同一时期，两剂疫苗的效力始终高于一剂疫苗。在衢州，应在儿童中实施两剂次 MMR 疫苗接种计划。第二剂的最佳年龄需要进一步评估。
